final results of the phase 3 data trial assessing aromatase inhibition in hr breast cancer
Published 2 years ago • 169 plays • Length 0:53Download video MP4
Download video MP3
Similar videos
-
2:21
updated results by duration of prior cdk4/6i in the met setting of the phase iii emerald trial
-
1:57
monarcher: final os results of abemaciclib in hr , her breast cancer
-
5:06
safety outcomes in the phase iii monarche trial of abemaciclib et in hr , her2- breast cancer
-
0:52
patient eligibility in the ameera-6 trial of amcenestrant
-
2:17
design and results of phase iii falcon trial of fulvestrant for advanced breast cancer
-
2:46
ameera-3: amcenestrant does not improve pfs in er /her2- breast cancer
-
10:15
monaleesa-3 os results: fulvestrant/ribociclib in postmenopausal hr /her2- advanced breast cancer
-
1:47
an overview of the ma17r trial in breast cancer
-
1:00
therapeutic strategies to maximize sensitivity to endocrine therapy in breast cancer
-
1:13
dr. pagani discusses aromatase inhibitors for premenopausal women with breast cancer
-
4:20
adjuvant treatment guidelines in post-menopausal women with breast cancer
-
7:06
everolimus extends pfs for hr positive, her2 negative breast cancer
-
1:21
phase iii trial of denosumab for breast cancer risk reduction in brca1 carriers
-
6:56
analyses from paloma-3 study, including os data for hr breast cancer
-
1:51
ameera-3: serd for er her2- breast cancer
-
5:00
penelope-b: palbociclib with endocrine therapy in hr , her2-negative breast cancer
-
6:44
overall survival (os) results of the phase iii monaleesa-3 trial
-
2:55
practical implications of the monaleesa-3 trial
-
0:06
breast cancer survivor: do this for hormone therapy joint pain relief